February 2024

New Products

• Tebentafusp (Kimmtrak) is a bispecific fusion protein, comprised of a T cell receptor (TCR) fused to an antibody fragment with specificity for the CD3 (cluster of differentiation 3) receptor, found on polyclonal T cells. The TCR has specificity for a gp100 peptide (expressed preferentially in melanoma cells) presented by human leukocyte antigen‑A*02:01 (HLA‑A*02:01). In vitro, tebentafusp bound to HLA‑A*02:01‑positive uveal melanoma cells and activated polyclonal T cells to release inflammatory cytokines and cytolytic proteins, which results in direct lysis of uveal melanoma tumour cells. Kimmtrak is indicated for the treatment of HLA‑A*02:01‑positive adult patients with unresectable or metastatic uveal melanoma. Kimmtrak concentrate for intravenous infusion contains tebentafusp 0.1 mg per 0.5 mL and is available in packs of 1 vial.

New Indications

• Raxtozinameran (Comirnaty Omicron XBB.1.5) is now indicated for active immunisation to prevent COVID‑19 in individuals 6 months of age and older in accordance with official recommendations.
   
• Tozinameran and famtozinameran (Comirnaty Original/Omicron BA.4-5) is now indicated (with provisional approval) for active immunisation to prevent COVID‑19 in individuals 5 years of age and older in accordance with official recommendations.
   
• Vosoritide (Voxzogo) is now indicated for the treatment of achondroplasia in all paediatric patients whose epiphyses are not closed.

New Contraindications

• Iopromide (Ultravist 300 and 370) are now contraindicated for intrathecal use.
   
• Metoclopramide hydrochloride (Maxolon) tablets are now contraindicated in children below 15 years of age.
   
• Rifabutin (Mycobutin) is now contraindicated for concomitant use with rilpivirine prolonged-release suspension for injection.

This list is a summary of only some of the changes that have occurred over the last month.
Before prescribing, always refer to the full product information.